razoxane has been researched along with Body Weight in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (48.15) | 18.7374 |
| 1990's | 8 (29.63) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alpert, L; Bernier, M; Chalifour, LE; Dostanic, S; Héon, S; Kirby, GM; Servant, N; Wang, C | 1 |
| de Vries, EG; Perik, PJ; van den Berg, MP; van Veldhuisen, DJ | 1 |
| Adamcová, M; Gersl, V; Hrdina, R; Kaplanová, J; Klimtová, I; Mazurová, Y; Simůnek, T; Sterba, M | 1 |
| Chen, Y; Deng, HY; Huang, GY; Li, K; Ng, PC; Pong, NH; Sung, RY; Tu, L; Xiang, P; Zhang, L; Zhao, H | 1 |
| Ferrans, VJ; Herman, EH | 4 |
| El-Hage, AN; Ferrans, VJ; Herman, EH; Witiak, DT | 1 |
| Gilbert, JM; Kark, AE; Slavin, G; Thompson, EM | 1 |
| Ardalan, B; Ferrans, VJ; Herman, EH; Jordan, W | 1 |
| Finch, MD; Hellmann, K; Trevan, D; Wang, G | 1 |
| Ferrans, VJ; Herman, EH; Zhang, J | 1 |
| Bast, A; Beems, DB; de Jong, J; Madhuizen, HT; van Acker, SA; van der Vijgh, WJ; Voest, EE | 1 |
| Bast, A; Grimbergen, JA; Kramer, K; van Acker, SA; van der Vijgh, WJ; Voest, EE; Zhang, J | 1 |
| Della Torre, P; Imondi, AR; Mazué, G; Moneta, D; Podestà, A; Sammartini, U | 1 |
| Chadwick, DP; Ferrans, VJ; Herman, EH; Zhang, J | 1 |
| Bajgar, J; Cerman, J; Gersl, V; Hrdina, R; Machácková, J; Mazurová, Y; Suba, P | 1 |
| Mantle, D; Preedy, VR; Richardson, PJ; Tesar, V; Zima, T | 1 |
| Ardalan, B; Bier, C; Herman, E; Krop, S; Waravdekar, V | 1 |
| Creighton, AM; Hopewell, JW; Jaenke, RS; Wilding, D; Yeung, TK | 1 |
| Baba, H; Bull, JM; Newman, RA; Ohno, S; Siddik, ZH; Stephens, LC; Strebel, FR | 1 |
| Dardir, M; Ferrans, VJ; Herman, EH | 1 |
| el-Hage, A; Ferrans, VJ; Herman, EH | 1 |
| Ferrans, VJ; Hamlin, RL; Herman, EH; Young, RS | 1 |
| Bhat, HB; Ferrans, VJ; Herman, EH; Witiak, DT | 1 |
| Creighton, AM; el-Hage, AN; Ferrans, VJ; Herman, EH; Witiak, DT | 1 |
27 other study(ies) available for razoxane and Body Weight
| Article | Year |
|---|---|
Dexrazoxane does not protect against doxorubicin-induced damage in young rats.
Topics: Age Factors; Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Body Weight; Cell Differentiation; Doxorubicin; Female; Heart Diseases; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Myocardium; Myocytes, Cardiac; Organ Size; Oxidative Stress; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Razoxane; Vesicular Transport Proteins | 2003 |
Experimental animal model for anthracycline-induced heart failure.
Topics: Animals; Anthracyclines; Body Weight; Cardiovascular Agents; Disease Models, Animal; Heart Failure; Heart Rate; Models, Cardiovascular; Razoxane; Stroke Volume | 2004 |
Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Biomarkers; Body Weight; Cardiovascular Agents; Daunorubicin; Disease Models, Animal; Dose-Response Relationship, Drug; Echocardiography; Erythrocyte Indices; Heart Failure; Heart Rate; Heart Ventricles; Male; Models, Cardiovascular; Myocardium; Myocytes, Cardiac; Rabbits; Razoxane; Stroke Volume; Time Factors | 2004 |
Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Topics: Animals; Antibiotics, Antineoplastic; Blotting, Western; Body Weight; Cardiomyopathies; Chelating Agents; Doxorubicin; Echocardiography; Extracellular Signal-Regulated MAP Kinases; Male; Microscopy, Electron; Mitochondria, Heart; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardium; Organ Size; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Razoxane; Up-Regulation | 2009 |
Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine.
Topics: Animals; Body Weight; Cardiomyopathies; Doxorubicin; Female; Male; Piperazines; Razoxane; Swine; Swine, Miniature; Vitamin E | 1983 |
Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters.
Topics: Animals; Body Weight; Cricetinae; Daunorubicin; Male; Mesocricetus; Piperazines; Razoxane; Time Factors | 1983 |
Inhibition of experimental colorectal cancer by razoxane (ICRF-159).
Topics: 1,2-Dimethylhydrazine; Animals; Body Weight; Carcinogens; Colonic Neoplasms; Dimethylhydrazines; Drug Administration Schedule; Female; Piperazines; Random Allocation; Rats; Rats, Inbred Strains; Razoxane; Rectal Neoplasms | 1984 |
Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
Topics: Animals; Antineoplastic Agents; Blood Chemical Analysis; Body Weight; Calcium; Daunorubicin; Heart; Male; Myocardium; Piperazines; Rabbits; Razoxane | 1981 |
Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).
Topics: Animals; Blood Cell Count; Body Weight; Dogs; Doxorubicin; Female; Heart; Hematocrit; Hemoglobins; Injections, Intraperitoneal; Male; Myocardium; Piperazines; Razoxane | 1981 |
Reduction of daunomycin toxicity by razoxane.
Topics: Animals; Body Weight; Daunorubicin; Dose-Response Relationship, Drug; Female; Intestines; Mice; Piperazines; Razoxane | 1981 |
Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cardiomyopathies; Deferoxamine; Doxorubicin; Heart Rate; Injections, Intraperitoneal; Injections, Intravenous; Kidney Diseases; Male; Rats; Rats, Inbred SHR; Razoxane | 1994 |
Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.
Topics: Animals; Body Weight; Cardiomyopathies; Dogs; Doxorubicin; Female; Male; Razoxane; Time Factors | 1993 |
Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.
Topics: Animals; Body Weight; Colforsin; Doxorubicin; Drug Administration Schedule; Free Radical Scavengers; Heart; Heart Rate; Hydroxyethylrutoside; Injections, Intraperitoneal; Injections, Intravenous; Isoproterenol; Male; Mice; Mice, Inbred BALB C; Myocardial Contraction; Myocardium; Razoxane; Time Factors | 1993 |
Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Body Weight; Cardiomyopathies; Cardiovascular Agents; Doxorubicin; Drug Interactions; Electrocardiography; Heart; Heart Atria; Heart Rate; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Razoxane; Telemetry | 1996 |
Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
Topics: Aging; Animals; Antineoplastic Agents; Body Weight; Cardiomyopathies; Chelating Agents; Doxorubicin; Erythrocytes; Growth; Leukocytes; Male; Organ Size; Rats; Rats, Sprague-Dawley; Razoxane; Weaning | 1999 |
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Doxorubicin; Heart Diseases; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Radiation-Protective Agents; Rats; Rats, Inbred SHR; Razoxane | 2000 |
Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits.
Topics: Acetylcholinesterase; Animals; Antibiotics, Antineoplastic; Body Weight; Butyrylcholinesterase; Cardiomyopathies; Cardiovascular Agents; Daunorubicin; Heart; Male; Myocardium; Rabbits; Razoxane; Ventricular Function, Left | 1999 |
Effects of Doxorubicin (Adriamycin) and [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)]propane (ICRF-187) on skeletal muscle protease activities.
Topics: Animals; Antibiotics, Antineoplastic; Body Weight; Chelating Agents; Doxorubicin; Endopeptidases; Lysosomes; Male; Muscle, Skeletal; Rats; Rats, Wistar; Razoxane; Time Factors | 2001 |
Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters.
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Cricetinae; Daunorubicin; Heart Diseases; Liver; Liver Diseases; Male; Mesocricetus; Myocardium; Piperazines; Rats; Razoxane; Stereoisomerism; Time Factors | 1979 |
The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
Topics: Animals; Body Weight; Cardiac Output; Dose-Response Relationship, Drug; Doxorubicin; Heart; Heart Diseases; Heart Failure; Heart Rate; Hemorrhage; Male; Pleural Effusion; Rats; Rats, Inbred Strains; Razoxane; Time Factors | 1992 |
Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
Topics: Animals; Blood Cell Count; Body Weight; Combined Modality Therapy; Doxorubicin; Female; Heart Diseases; Hematopoiesis; Hyperthermia, Induced; Kidney Diseases; Nervous System Diseases; Rats; Rats, Inbred F344; Razoxane; Sarcoma, Experimental; Survival Analysis | 1991 |
Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Drug Evaluation, Preclinical; Drug Interactions; Epirubicin; Heart; Kidney; Male; Microscopy, Electron; Myocardium; Piperazines; Rats; Rats, Inbred SHR; Razoxane; Stereoisomerism | 1989 |
Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits.
Topics: Animals; Blood Cell Count; Body Weight; Cardiomyopathies; Daunorubicin; Drug Administration Schedule; Drug Interactions; Hemoglobins; Injections, Intraperitoneal; Injections, Intravenous; Male; Piperazines; Rabbits; Razoxane | 1986 |
Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
Topics: Animals; Blood Pressure; Body Weight; Doxorubicin; Drug Interactions; Heart Diseases; Heart Rate; Kidney Diseases; Male; Piperazines; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Razoxane; Species Specificity | 1988 |
Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
Topics: Animals; Blood; Body Weight; Dogs; Doxorubicin; Echocardiography; Electrocardiography; Female; Heart; Male; Myocardium; Piperazines; Razoxane | 1988 |
Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
Topics: Animals; Blood Cell Count; Body Weight; Dogs; Doxorubicin; Drug Evaluation, Preclinical; Female; Heart Diseases; Hematocrit; Hematologic Diseases; Male; Piperazines; Razoxane | 1987 |
Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters.
Topics: Animals; Body Weight; Cricetinae; Daunorubicin; Male; Mesocricetus; Piperazines; Razoxane; Stereoisomerism; Structure-Activity Relationship | 1985 |